a Stony Brook University , School of Pharmacy and Pharmaceutical Sciences , Stony Brook , NY , USA.
b Stony Brook University , School of Medicine , Stony Brook , NY , USA.
Am J Drug Alcohol Abuse. 2018;44(4):418-425. doi: 10.1080/00952990.2017.1362418. Epub 2017 Oct 5.
The Clinical Institute Withdrawal Assessment-Alcohol, Revised (CIWA-Ar) is an assessment tool used to quantify alcohol withdrawal syndrome (AWS) severity and inform benzodiazepine treatment for alcohol withdrawal.
To evaluate the prescribing patterns and appropriate use of the CIWA-Ar protocol in a general hospital setting, as determined by the presence or absence of documented AWS risk factors, patients' ability to communicate, and provider awareness of the CIWA-Ar order.
This retrospective chart review included 118 encounters of hospitalized patients placed on a CIWA-Ar protocol during one year. The following data were collected for each encounter: patient demographics, admitting diagnosis, ability to communicate, and admission blood alcohol level; and medical specialty of the clinician ordering CIWA-Ar, documentation of the presence or absence of established AWS risk factors, specific parameters of the protocol ordered, service admitted to, provider documentation of awareness of the active protocol within 48 h of initial order, total benzodiazepine dose equivalents administered and associated adverse events.
57% of patients who started on a CIWA-Ar protocol had either zero or one documented risk factor for AWS (19% and 38% respectively). 20% had no documentation of recent alcohol use. 14% were unable to communicate. 19% of medical records lacked documentation of provider awareness of the ordered protocol. Benzodiazepine associated adverse events were documented in 15% of encounters.
The judicious use of CIWA-Ar protocols in general hospitals requires mechanisms to ensure assessment of validated alcohol withdrawal risk factors, exclusion of patients who cannot communicate, and continuity of care during transitions.
修订后的临床戒断评估-酒精量表(CIWA-Ar)是一种评估工具,用于量化酒精戒断综合征(AWS)的严重程度,并为酒精戒断的苯二氮䓬类药物治疗提供依据。
通过评估有无记录的 AWS 风险因素、患者的沟通能力以及医务人员对 CIWA-Ar 医嘱的知晓情况,评估在综合医院环境中使用 CIWA-Ar 方案的开具模式和恰当性。
本回顾性图表分析纳入了 118 例在一年内接受 CIWA-Ar 方案治疗的住院患者。每个患者的数据如下:患者人口统计学特征、入院诊断、沟通能力和入院时的血酒精水平;以及开具 CIWA-Ar 的临床医生的医疗专业、有无记录的既定 AWS 风险因素、所开方案的具体参数、收治科室、医务人员在初始医嘱后 48 小时内对正在执行的方案的知晓情况记录、所给予的苯二氮䓬类药物等效剂量和相关不良反应。
开始使用 CIWA-Ar 方案的患者中,有 57%(分别为 19%和 38%)仅有 0 或 1 个 AWS 风险因素记录。20%的患者无近期饮酒记录。14%的患者无法沟通。19%的病历缺乏医务人员知晓所开医嘱的记录。15%的就诊记录中记录了苯二氮䓬类药物相关的不良反应。
在综合医院中合理使用 CIWA-Ar 方案需要有机制来确保评估经证实的酒精戒断风险因素、排除无法沟通的患者,并在转科过程中保持医疗连续性。